Now that ropeginterferon is approved for PV, how do you select patients for this therapy?
Answer from: at Academic Institution
First, I have no conflicts of interest with respect to ropeginterferon (rPegIFN). rPegIFN is a long-acting version (once every two weeks administration) of pegylated interferon (PegIFN) as opposed to once per week, which has been used for decades for the treatment of CML and MPN patients, without ra...
Comments
at Kaiser Permanente, Los Angeles Med Center Thank you so much for your detailed response, Dr. ...
at Mount Sinai To which age groups would you limit rPegIFN partic...
at Johns Hopkins University I have never considered age in using interferon or...
Thank you so much for your detailed response, Dr. ...
To which age groups would you limit rPegIFN partic...
I have never considered age in using interferon or...